Reason reports back from Rejuvenation Startup Summit 2024
Fight Aging! - 13-May-2024A great summary of 25 speakers who are in various stages of platform building, drug discovery and clinical trials
Matthew Scholz
Founder and Chief Executive Officer at Oisín Biotechnologies
Matthew Scholz is the founder and Chief Executive Officer of Immusoft, a biotech start-up firm that is developing a breakthrough technology that will turn a patient’s B cells into miniature drug factories. Longer term, this technology has the potential to transform the landscape of biomedicine.
See also: 
Oisin Biotechnologies
- Drug development company focused on the senolytic technology to fight age-related diseases
Details last updated 15-May-2020
Matthew Scholz is also referenced in the following:
Body-wide Gene Therapy with Proteo-Lipid Vehicles - Matthew Scholz at Longevity Summit Dublin 2024
Matthew Scholz delivered a keynote on body-wide gene therapy using proteo-lipid vehicles
Matthew Scholz News
Oisín Biotechnologies' gene therapy may be available in the next 5 years
Longevity Technology - 22-Jan-2021Results in mice suggest that it can increase median lifespan in humans by 15 years
Nature Biotechnology reviews the state of play of senolytics
Nature Biotechnology - 12-Nov-2020In August, Unity announced that its lead drug candidate had failed to beat a placebo in reducing ...
OncoSenX raises more funds for cancer therapy, plans for clinical trial
GeekWire - 11-May-2020Allowing developments on tech that will kill cancer based on their genetics
Oisín made it to top 10 breakthrough technologies of 2020
Business Wire - 26-Feb-2020Will begin clinical trials after completing pre-clinical studies
